MetaCap

Kalaris Therapeutics (KLRS) vs Metagenomi Therapeutics (MGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Metagenomi Therapeutics (MGX) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 62.6% versus a loss of 81.7%. Kalaris Therapeutics is the larger company by market cap ($30.5 million vs $21.4 million), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KLRS-81.74%MGX-62.58%
+64%-13%-89%
Nov 21, 20251 yearNov 20, 2026
KLRS-92.27%MGX-94.52%
+39%-31%-101%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KLRS versus MGX key metrics
MetricKLRSMGX
Share price$1.28$0.565
Market cap$30.47M$21.36M
1-day change-5.19%-7.95%
YTD return-84.83%-65.12%
1-year return-81.74%-62.58%
5-year return-99.70%—
EPS (TTM)$-1.84$-2.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$25.21M
Revenue growth (YoY)—-51.79%
Net income (latest FY)$-43.44M$-87.87M
Operating margin—-380.85%
Net margin—-348.54%
52-week high$11.88$1.87
52-week low$1.25$0.562
Distance from 52-week high-89.23%-69.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1361.72%+1138.94%
Average volume77.37K163.21K
Shares outstanding23.80M37.81M
Employees20113
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MGX has outperformed KLRS by 19.2 percentage points over the past year.

About Kalaris Therapeutics

KLRS stock →

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees

About Metagenomi Therapeutics

MGX stock →

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

KLRS vs MGX FAQ

Which is bigger, Kalaris Therapeutics or Metagenomi Therapeutics?

Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $30.47M compared with $21.36M for Metagenomi Therapeutics (MGX).

Which stock has performed better over the past year, KLRS or MGX?

MGX returned -62.58% over the past 12 months, compared with -81.74% for KLRS (price return, excluding dividends). Past performance does not predict future results.

Are Kalaris Therapeutics and Metagenomi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons